Dr. Andrea Chiricozzi is a Senior Researcher at the Department of Translational Medicine and Surgery, Dermatology Unit, Catholic University of Rome and is a dermatologist at the Fondazione Policlinico Universitario A. Gemelli I.R.C.C.S. Hospital. He qualified in medicine at the University Campus Bio-Medico in Rome, Italy in 2007. In 2012, he completed his residency training in dermatology at the University of Rome Tor Vergata and received the Italian Board Certificate in Dermatology and Venereology. He worked as a dermatologist in the Department of Dermatology at the University of Rome Tor Vergata, until 2015. He was appointed as researcher at the Department of Translation and Clinical Medicine, Dermatology Unit, University of Pisa from 2016 to 2019. His scientific interests include skin immunology and inflammatory skin disorders, namely psoriasis, atopic dermatitis, and hidradenitis suppurativa. In particular, his scientific interests have been focused on the pathophysiology underlying psoriatic plaque formation. His scientific activity on immune-mediated skin disorders was further developed at the Laboratory for Investigative Dermatology, headed by Professor James G. Krueger at the Rockefeller University in New York, USA, as a postdoctoral fellow and visiting dermatologist. He has been an investigator for multiple clinical trials testing biologic therapeutics, and new oral and topical drugs for inflammatory skin disorders. He contributed as an author to the most recent Italian Guidelines for the treatment of psoriasis, and he has been involved in the Italian Registry for Biosimilars in Psoriasis and Psoriatic Arthritis (PsO biosimilars registry). He is the author of more than 100 peer-reviewed articles and four book chapters. He was honored with the prestigious Leo-Pharma Research Silver Award in 2012.
Areas of Interest
Targeted therapies (biologicals and small molecules), immune mechanisms and more in general pathophysiology of psoriasis.
Involvement with Other Organization(s)
Close collaboration with patient organizations by contributing to their meeting as faculty, helping with access-to-cure for “peculiar patients” (example, indigents).